Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 100 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Natriuretic Peptides Clear all
Completed Phase 1Phase 2 Interventional Results available

Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.

NCT00405548
View directory record Official record
Conditions
Left Ventricular Diastolic Dysfunction
Interventions
BNP (nesiritide), Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 8, 2026, 2:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Beige Fat, Energy, and the Natriuretic Peptide System

NCT04357964
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 55 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 8, 2026, 2:13 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Ponsegromab in People With Heart Failure

NCT05492500
View directory record Official record
Conditions
Heart Failure
Interventions
Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 8, 2026, 2:13 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Enhancing the Natriuretic Peptide System in HFpEF

NCT05279742
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
Interventions
MANP, Sacubitril/Valsartan, Oral Placebo, Injection Placebo
Drug
Lead sponsor
Horng Chen
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 8, 2026, 2:13 AM EDT
Completed No phase listed Observational

Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients

NCT01023451
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 8, 2026, 2:13 AM EDT
Terminated No phase listed Observational

Serial BNP Testing for Heart Failure Management

NCT00622531
View directory record Official record
Conditions
Heart Failure
Interventions
BNP assay (Siemens ADVIA Centaur BNP), hidden BNP value
Device · Other
Lead sponsor
Siemens Healthcare Diagnostics Inc
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Palo Alto, California • New York, New York • Poughkeepsie, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 8, 2026, 2:13 AM EDT
Completed No phase listed Observational

RISK Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Receiving CRT-D

NCT00453622
View directory record Official record
Conditions
Heart Failure
Interventions
Cardiac Resynchronization Therapy-Defibrillator
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 90 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 8, 2026, 2:13 AM EDT
Withdrawn Phase 4 Interventional

Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD

NCT04192110
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Diuretic initiation or augmentation
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 8, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

NCT06593600
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome (POTS)
Interventions
REGN7544, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Gilbert, Arizona • Carlsbad, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 8, 2026, 2:13 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading

NCT01763541
View directory record Official record
Conditions
Hypertension
Interventions
leuprolide acetate, Anastrozole
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 8, 2026, 2:13 AM EDT
Completed No phase listed Observational

Utility of Serial BNP Levels in Emergency Department CHF

NCT00534066
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2007 · Synced Oct 8, 2026, 2:13 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

NCT03197766
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 18 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 8, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia

NCT03583697
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Up to 59 Months
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 8, 2026, 2:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Diagnosing Natriuretic Peptide Deficiency

NCT03035929
View directory record Official record
Conditions
Healthy, Lean
Interventions
Dexamethasone
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 8, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients

NCT01941225
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Inhaled iloprost 5.0 mcg, Placebo
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 8, 2026, 2:13 AM EDT
Terminated Phase 4 Interventional

Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure

NCT00293150
View directory record Official record
Conditions
Diastolic Heart Failure
Interventions
Eplerenone
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 8, 2026, 2:13 AM EDT
Recruiting Not applicable Interventional

Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"

NCT05919342
View directory record Official record
Conditions
Heart Failure, Cardiovascular Diseases
Interventions
NT-proBNP
Diagnostic Test
Lead sponsor
NHS Greater Glasgow and Clyde
Other
Eligibility
40 Years and older
Enrollment
3,904 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 8, 2026, 2:13 AM EDT
Completed No phase listed Observational

Blood Collection of Patient Presenting in the ED and Prescribed a BNP

NCT02614209
View directory record Official record
Conditions
Heart Failure
Interventions
In Vitro diagnostic tests
Device
Lead sponsor
Fujirebio Diagnostics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 8, 2026, 2:13 AM EDT
Terminated Phase 4 Interventional Results available

Nesiritide and Renal Function After the Total Artificial Heart

NCT01836809
View directory record Official record
Conditions
Congestive Heart Failure, Cardiorenal Syndrome
Interventions
nesiritide, placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 8, 2026, 2:13 AM EDT
Completed No phase listed Observational

Access Natriuretic Peptide Assay(s) Pivotal - Emergency Department Subject Enrollment and Specimen Collection

NCT04169815
View directory record Official record
Conditions
Heart Failure
Interventions
Access Immunodiagnostic Products
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
21 Years and older
Enrollment
2,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
15
States / cities
Loma Linda, California • Sacramento, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 8, 2026, 2:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Plasma Brain Natriuretic Peptide Levels in Pregnancy

NCT00324402
View directory record Official record
Conditions
Cardiomyopathy, Pregnancy
Interventions
Not listed
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 8, 2026, 2:13 AM EDT
Completed No phase listed Observational

Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF

NCT00693745
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Not listed
Lead sponsor
Abbott RDx Cardiometabolic
Other
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
San Diego, California • Brooklyn, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2010 · Synced Oct 8, 2026, 2:13 AM EDT
Terminated Phase 4 Interventional Results available

The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

NCT02253394
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan plus Spironolactone, Ambrisentan plus Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 8, 2026, 2:13 AM EDT
Active, not recruiting Phase 3 Interventional

Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

NCT06455059
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Vosoritide, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
3 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 8, 2026, 2:13 AM EDT